1. Home
  2. SLBT vs ADNT Comparison

SLBT vs ADNT Comparison

Compare SLBT & ADNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SL Science Holding Limited Ordinary Shares

SLBT

SL Science Holding Limited Ordinary Shares

N/A

Current Price

$2.65

Market Cap

1.5B

Sector

N/A

ML Signal

N/A

Logo Adient plc

ADNT

Adient plc

HOLD

Current Price

$21.04

Market Cap

1.5B

ML Signal

HOLD

Company Overview

Basic Information
Metric
SLBT
ADNT
Founded
N/A
2016
Country
Taiwan
Ireland
Employees
20
N/A
Industry
Auto Parts:O.E.M.
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.5B
IPO Year
N/A
2016

Fundamental Metrics

Financial Performance
Metric
SLBT
ADNT
Price
$2.65
$21.04
Analyst Decision
Buy
Analyst Count
0
11
Target Price
N/A
$25.41
AVG Volume (30 Days)
145.3K
858.9K
Earning Date
N/A
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.06
Revenue
N/A
$17,439,000,000.00
Revenue This Year
N/A
$2.71
Revenue Next Year
N/A
$2.36
P/E Ratio
N/A
$366.75
Revenue Growth
N/A
7.56
52 Week Low
$2.54
$17.68
52 Week High
$6.25
$27.32

Technical Indicators

Market Signals
Indicator
SLBT
ADNT
Relative Strength Index (RSI) 35.84 49.86
Support Level N/A $20.23
Resistance Level $4.91 $23.72
Average True Range (ATR) 0.37 0.91
MACD -0.14 0.21
Stochastic Oscillator 7.91 43.54

Price Performance

Historical Comparison
SLBT
ADNT

About SLBT SL Science Holding Limited Ordinary Shares

SL Science Holding Ltd is a biomedical company specialized in developing cellular and gene therapies advancing regenerative medicine and cancer treatment. It utilizes immune stem cells to target cancer and bovine-derived milk exosomes to regenerate damaged tissues, thus potentially offering expansive medical applications for its products. With proprietary technologies such as Armed-T and Gamma Delta T cells, as well as exosome applications in skincare and cancer recovery. It operates in three segments namely Exosome products, CD-19 Armed-T products, and GDT cell therapy products. It derives revenue from Exosome products segment.

About ADNT Adient plc

Adient began trading Oct. 31, 2016, when Johnson Controls spun off its automotive experience segment. Adient is a leading seating supplier to the industry with about a midteens share of the global market including unconsolidated joint venture business. Its share in China is around 20%, down from about 45%, following the sale of its main joint venture there at the end of fiscal 2021. Unconsolidated revenue from joint ventures was about $3.5 billion in fiscal 2025 and consolidated China revenue was $1.3 billion. The company is headquartered in Ireland but has corporate offices in the Detroit area. Fiscal 2025 (Sept. 30 year-end) consolidated revenue, which excludes joint venture sales, was $14.5 billion.

Share on Social Networks: